Tin tức & Cập nhật
Xem bài viết Tim mạch
Xem
Chỉ hiển thị Multimedia

Fewer major bleeds with prasugrel as default antiplatelet after PCI
04 Oct 2026
bởiElvira Manzano
When prasugrel is the default antiplatelet for patients with acute coronary syndromes (ACS) undergoing PCI*, fewer major bleeds occur than when ticagrelor is the default, according to the SWITCH-SWEDEHEART study presented at ESC 2026. This benefit is not accompanied by increased ischaemic events.
04 Oct 2026

Early PCSK9 inhibition post-MI lowers LDL-C: Does it influence clinical outcomes?
03 Oct 2026
bởiElvira Manzano
Initiating the PCSK9* inhibitor evolocumab in the cath lab prior to PCI** in patients with acute myocardial infarction (MI) dramatically lowers LDL-C compared with standard care in the phase IV AMUNDSEN trial presented at ESC 2026.
03 Oct 2026






